Ignite Creation Date:
2024-05-05 @ 10:52 PM
Last Modification Date:
2024-10-26 @ 10:25 AM
Study NCT ID:
NCT01204177
Status:
COMPLETED
Last Update Posted:
2013-09-06
First Post:
2010-09-16
Brief Title:
Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Phase II Trial of BAY86-9766 Plus Sorafenib as First Line Systemic Treatment for Hepatocellular Carcinoma HCC
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BASIL
Brief Summary:
This study investigates the safety and efficacy of the combination therapy with BAY86-9766 and sorafenib in patients with liver cancer Safety will be determined by laboratory and other evaluations Efficacy of the combination BAY86-9766 and sorafenib will be determined by disease control rate overall survival time to progression response rate and duration of response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None